Sales Of Generic Injectables Industry Are Predicted To Rise At A Healthy CAGR Of 12.3% From 2021 To 2031

𝐆𝐞𝐧𝐞𝐫𝐢𝐜 𝐈𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧

According to the report, the global generic injectables market was valued at US$ 83.09 Bn in 2020 and is expected to cross US$ 307.7 Bn at a CAGR of 12.3% from 2021 to 2031. Generic injectables are becoming more popular in the medical field for treatment of various diseases such as cancer, diabetes, and cardiac. Key market players focus on manufacturing cost-effective generic injectables. The global generic injectables market is anticipated to be driven by increase in number of elderly patients, prevalence of diseases, number of regulatory approvals, and demand for generic injectables.

Asia Pacific held a major share of the global generic injectables market in 2020 due to presence of large number of key players, rise in demand for generic injectables, and increase in chronic diseases. The generic injectables market in Asia Pacific is expected to expand at a high CAGR of 13.6% from 2021 to 2031, due to surge in the number of elderly patients and increase in approval from regulatory authorities

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐚 𝐬𝐚𝐦𝐩𝐥𝐞 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 (𝐔𝐬𝐞 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐌𝐚𝐢𝐥 𝐈𝐝 𝐟𝐨𝐫 𝐐𝐮𝐢𝐜𝐤 𝐑𝐞𝐬𝐩𝐨𝐧𝐬𝐞) - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=42698

𝐀𝐝𝐯𝐞𝐧𝐭 𝐨𝐟 𝐍𝐞𝐰 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐭𝐨 𝐃𝐫𝐢𝐯𝐞 𝐌𝐚𝐫𝐤𝐞𝐭

The rise in the prevalence of various diseases such as cancer, diabetes, cardiac and others has fueled the demand for generic injectables. Teva Pharmaceutical Industries announced the USFDA acceptance of its BLA for the proposed biosimilar Trastuzumab for review. The biosimilar (CT-P6) is being developed by Celltrion, Inc. and Teva together for the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. Sun Pharma launched complete range of generic anti-epilepsy drugs. Brivaracetam has been approved by the Drug Controller General of India (DCGI) as an adjunctive therapy in treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.

Sanofi announced the U.S. FDA approval of once-daily Soliqua 100/33 (insulin glargine & lixisenatide injection) 100 units/mL & 33 mcg/mL for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units daily).

Pfizer, Inc. focuses on the development of biosimilar formulations in key therapeutic areas, owing to its potential to improve patient care by extending access to high quality, effective, targeted treatment for multiple serious and chronic diseases.

Sandoz announced the U.S. FDA approval and launch of Glatopa 40 mg/ml, which is a fully substitutable, AP-rated generic version of Copaxone (glatiramer acetate injection) 40 mg/ml. Glatopa was developed as per a collaboration agreement between Momenta Pharmaceuticals, Inc. and Sandoz. It is produced in the U.S.

𝐋𝐚𝐫𝐠𝐞 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞 𝐈𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞𝐬 𝐃𝐨𝐦𝐢𝐧𝐚𝐭𝐞𝐝 𝐆𝐞𝐧𝐞𝐫𝐢𝐜 𝐈𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭

In terms of product type, the global generic injectables market can be bifurcated into large injectable molecules and small injectable molecules. The large injectable molecules segment dominated the global generic injectables market in 2020, and the trend is projected to continue during the forecast period. The increase in the demand for large injectable molecules such as monoclonal antibodies and insulin is expected to drive the segment over the next few years.

𝐁𝐮𝐲 𝐭𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 | 𝐈𝐦𝐦𝐞𝐝𝐢𝐚𝐭𝐞 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐚𝐭 - https://www.transparencymarketresearch.com/checkout.php?rep_id=42698<ype=S

𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐭𝐨 𝐎𝐟𝐟𝐞𝐫 𝐆𝐫𝐨𝐰𝐭𝐡 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬

Based on application, the global generic injectables market can be classified into oncology, infectious diseases, diabetes, cardiology, immunology, and others. The oncology segment dominated the global generic injectables market in 2020, and the trend is projected to continue during the forecast period. The rise in prevalence of cancer is expected to drive the segment in the near future.

𝐕𝐢𝐚𝐥𝐬 𝐭𝐨 𝐋𝐞𝐚𝐝 𝐆𝐞𝐧𝐞𝐫𝐢𝐜 𝐈𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭

In terms of container type, the global generic injectables market has been categorized into vials, premix, prefilled syringes, ampoules, and others. The vials segment accounted for a major share of the market in 2020. The segment is projected to register highest market attractiveness index by 2031.

𝐈𝐧𝐭𝐫𝐚𝐯𝐞𝐧𝐨𝐮𝐬 𝐭𝐨 𝐛𝐞 𝐏𝐫𝐞𝐟𝐞𝐫𝐫𝐞𝐝 𝐑𝐨𝐮𝐭𝐞 𝐨𝐟 𝐀𝐝𝐦𝐢𝐧𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧

In terms of route of administration, the global generic injectables market has been divided into intravenous, intramuscular, subcutaneous, and others. The intravenous segment held a major share of the global generic injectables market in 2020. Increase in the geriatric population, surge in focus on manufacturing of injectables, and rise in prevalence of chronic diseases across the globe are projected to propel the intravenous segment.

𝐀𝐬𝐢𝐚 𝐏𝐚𝐜𝐢𝐟𝐢𝐜 𝐭𝐨 𝐛𝐞 𝐋𝐮𝐜𝐫𝐚𝐭𝐢𝐯𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐟𝐨𝐫 𝐆𝐞𝐧𝐞𝐫𝐢𝐜 𝐈𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞𝐬

In terms of region, the global generic injectables market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Asia Pacific is projected to account for a leading share of the global generic injectables market during the forecast period, owing to the increase in the number of patients suffering from chronic diseases in hospitals. The rise in the number of approvals for new ANDA by FDA boosts the demand for generic injectables.

The generic injectables market in Asia Pacific is projected to grow at a rapid pace over the next few years. India, China, and South Korea are expected to be lucrative markets in the near future.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐜𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=42698

𝐆𝐫𝐨𝐰𝐭𝐡 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬

Key players operating in the global generic injectables market are AstraZeneca, Baxter International, Inc., Biocon, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Hikma Pharmaceuticals plc, Johnson & Johnson Services, Inc., Lupin Ltd., Merck KGaA, Mylan N.V., Novartis AG (Sandoz International GmbH), Pfizer, Inc., Piramal Pharma Solutions, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

𝐆𝐥𝐨𝐛𝐚𝐥 𝐆𝐞𝐧𝐞𝐫𝐢𝐜 𝐈𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧

𝐆𝐞𝐧𝐞𝐫𝐢𝐜 𝐈𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐓𝐲𝐩𝐞
Large Molecule Injectables
Monoclonal Antibodies (mAbs)
Insulin
Others
Small Molecule Injectables

𝐆𝐞𝐧𝐞𝐫𝐢𝐜 𝐈𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧
Oncology
Infectious Diseases
Cardiology
Diabetes
Immunology
Others

𝐆𝐞𝐧𝐞𝐫𝐢𝐜 𝐈𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐂𝐨𝐧𝐭𝐚𝐢𝐧𝐞𝐫 𝐓𝐲𝐩𝐞
Vials
Premix
Prefilled Syringes
Ampoules
Others

𝐆𝐞𝐧𝐞𝐫𝐢𝐜 𝐈𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐑𝐨𝐮𝐭𝐞 𝐨𝐟 𝐀𝐝𝐦𝐢𝐧𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧
Intravenous
Intramuscular
Subcutaneous
Others

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 -

𝐃𝐫𝐮𝐠 𝐝𝐞𝐯𝐢𝐜𝐞 𝐂𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 - https://www.globenewswire.com/news-release/2022/04/19/2424699/0/en/Drug-device-Combination-Products-Market-to-Expand-at-CAGR-of-7-3-During-Forecast-Period-Notes-TMR-Study.html

𝐄𝐥𝐝𝐞𝐫𝐥𝐲 𝐚𝐧𝐝 𝐃𝐢𝐬𝐚𝐛𝐥𝐞𝐝 𝐀𝐬𝐬𝐢𝐬𝐭𝐢𝐯𝐞 𝐃𝐞𝐯𝐢𝐜𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 - https://www.einpresswire.com/article/576728332/elderly-and-disabled-assistive-devices-market-to-garner-us-31-6-bn-by-2028-at-5-3-cagr-finds-tmr

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.